首頁 > 市場調查報告書 > 製藥

生物製劑

到 2028 年的生物製藥市場預測——COVID-19 的影響以及按產品類型和應用進行的全球分析

市場調查報告書

商品編碼

1263764

到 2028 年的生物製藥市場預測——COVID-19 的影響以及按產品類型和應用進行的全球分析

Biopharmaceuticals Market Forecast to 2028 - Global Analysis By Product Type and Application

出版日期: 2023年03月22日 | 出版商:

The Insight Partners | 英文 346 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

生物製藥市場預計將從 2022 年的 32996622 萬美元增長到 2028 年的 70087394 萬美元，從 2022 年到 2028 年的複合年增長率為 13.4%。

有幾個因素推動了生物製藥市場的增長，包括越來越多地應用於抗癌藥物和治療罕見疾病的前景。

預計在預測期內，北美將繼續保持其在生物製藥市場的主導地位。到 2022 年，美國將佔據該地區最大的市場份額。根據國際貿易管理局的一份報告，美國是生物製藥研發的先行者，也是最大的市場，約佔全球生物製藥市場的三分之一。此外，生物製藥行業對美國經濟的經濟影響是巨大的。 2018 年，超過 170 億美元的生物製藥出口額來自大多數在美國經營的外國公司。此外，這些外國公司中的大多數同年在研發上花費了約 200 億美元。

另一方面，亞太地區有望在預測期內實現良好增長。這是因為中國的生物製藥行業正在經歷從單純仿製藥向創新中心的重大轉變。此外，產業化進程的推進和新藥、高端醫療器械和技術應用的擴大也是中國生物醫藥市場增長的因素。例如，2022 年 3 月，中國生物製藥先驅 CANbridge Pharmaceuticals Inc. 推出了 CAN108 [Malarixis dermatitis]，用於治療 1 歲及以上患有 Alagille 綜合徵 (ALGS) 患者的膽汁瘙癢症。宣布台灣食品和藥品監督管理局（TFDA）已受理 LIVMARLI TM 的新藥申請/孤兒藥註冊（NDA/ODR）。上述因素促成了 2022-2028 年亞太地區生物製藥市場的有影響力增長。

市場機會

加速臨床試驗

通過加速臨床試驗，我們將引領罕見病和常見遺傳病新藥的研發和商業化。 Blastoid 漿細胞樹突狀細胞腫瘤 (BPDCN) 是一種侵襲性急性白血病，傳統上難以診斷。這種疾病也極為罕見，在美國每年影響不到 1,000 名患者。 2018 年 12 月，Tagraxofusp 成為第一個獲批治療 BPDCN 的療法，並自此成為治療這些患者的標準療法。在臨床試驗中，超過 90% 的初治患者對治療有反應。

肌萎縮側索硬化症 (ALS) 是一種進行性神經退行性疾□□病，會削弱肌肉、影響身體機能，並對大腦和脊髓造成不可逆轉的損傷。目前，只有兩種產品被批准用於減緩與肌萎縮側索硬化相關的功能衰退。加速臨床試驗正在進行中，以開發針對 ALS 的新產品。例如，反義寡核甘酸 (ASO) 在 ALS 患者的臨床試驗中顯示出可喜的結果。此外，針對散發性和家族性 ALS 患者的多個突變的各種基因治療方法正在進行臨床試驗。

因此，臨床試驗中豐富的生物製藥管道有望在未來幾年為生物製藥市場提供有利可圖的增長機會。

按產品類型劃分，生物製藥市場分為單克隆抗體、重組疫苗、常規疫苗、重組生長因子、純化蛋白、重組蛋白、重組激素、重組□、細胞和基因療法、細胞因子/干擾素/白細胞介素，已分類在其他（基於 mRNA 的療法等）下。單克隆抗體部分將在 2022 年佔據最大的市場份額，預計在預測期內將實現顯著的複合年增長率。單克隆抗體（mAB）通過為免疫腫瘤學和免疫治療提供創新的治療方案，一直走在生物藥市場的前沿，並將繼續引領生物製藥市場的資源投資。我將繼續。 mAB 可治療多種疾病，包括癌症、器官移植排斥、炎症和自身免疫性疾病、過敏、感染、COVID-19、骨質疏鬆症、眼病、偏頭痛、高膽固醇和神經系統疾病。有許多不同的 mAB 用於治療癌症。它們以不同的方式殺死癌細胞或阻止它們生長。例如，曲妥珠單抗 (Herceptin) 和利妥昔單抗 (MabThera) 是通用名稱，末尾帶有“mab”。自從第一種含有單克隆抗體的藥物被批准用於人類以來，美國食品和藥物管理局 (FDA) 對單克隆抗體療法的批准有所增加。單克隆抗體的一大優勢是它們已經成功地製成了治療某些疾病的藥物，例如某些癌症。單克隆抗體的另一個優勢是它們比其他治療方法更精確。這可以提高療效並減少一些副作用。單克隆抗體質量是所有生產批次的標準，這對於治療和診斷用途都很重要。上述因素促進了細分市場的增長，並在預測期內推動了生物製藥市場。

按應用劃分，生物製藥市場分為癌症、炎症/傳染病、自身免疫性疾病、代謝紊亂、激素異常/生長障礙、心血管疾病、神經系統疾病等。到 2022 年，腫瘤學將佔市場規模的最大份額，但預計炎症和傳染病在預測期內的複合年增長率最高。根據美國國立衛生研究院 (NIH) 的一份報告，癌症是一種複雜的侵襲性遺傳病，在全球範圍內導致大量死亡率。例如，基於蛋白質的生物藥物已顯著延長了數百萬癌症患者的生命。此外，多家頂級公司已開展研究合作，以開髮用於癌症治療的新型治療藥物靶向蛋白質技術。例如，2022 年 4 月，Ubix Therapeutics 宣布與 SK Biopharmaceuticals 開展研究合作，利用 Ubix 的 Degraducer 技術開髮用於治療癌症的新型化合物和藥物。上述因素促進了細分市場的增長，從而促進了預測期內生物製藥市場的增長。

食品藥品監督管理局、日本對外貿易組織、沙特阿拉伯食品藥品監督管理局 (SFDA) 和美國醫院協會 (AHA) 是編寫生物製藥市場報告時參考的主要和次要信息來源。

內容

第一章介紹

調查範圍
Insight Partners 研究報告指南
市場細分
- 全球生物製藥市場 - 按產品類型
- 全球生物製藥市場 - 按應用
- 全球生物製藥市場 - 按地區

第 2 章生物製藥市場 - 要點

第三章研究方法論

報導
二次調查
關於初步調查

第 4 章生物製藥市場 - 市場狀況

害蟲分析
- 北美 PEST 分析
- 歐洲 PEST 分析
- 亞太地區 PEST 分析
- 中東和非洲 PEST 分析
- 拉丁美洲 PEST 分析
專家意見

第 5 章生物製藥市場 - 主要市場動態

市場驅動因素
- 推進抗癌藥物的應用
- 治療罕見病的潛力
市場製約因素
- 製造基礎設施成本高
市場機會
- 加速臨床試驗
未來趨勢
- 生物製藥的合同製造
影響分析

第 6 章生物製藥市場 - 全球分析

生物製藥全球市場收入、預測和分析
全球生物製藥市場，按地區劃分的預測和分析
主要參與者的市場定位

第 7 章全球生物製藥市場收入和到 2028 年的預測 - 按產品類型

2021 年和 2028 年按產品類型劃分的生物製藥市場銷售額份額 (%)
單克隆抗體
重組疫苗
常規疫苗
重組生長因子
純化蛋白
重組蛋白
重組激素
重組□
細胞和基因治療藥物
細胞因子/干擾素/白細胞介素
其他（基於 mRNA 的療法等）

第 8 章到 2028 年的全球生物製藥市場分析和預測 - 按應用

按應用劃分的全球生物製藥市場，2021 年和 2028 年 (%)
腫瘤科
炎症和傳染病
自身免疫性疾病
代謝綜合徵
激素異常和生長障礙
心血管疾病
神經系統疾病
其他治療用途

第 9 章生物製藥市場 - 收入和到 2028 年的預測 - 區域分析

北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 意大利
- 西班牙
- 其他歐洲
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳大利亞
- 其他亞太地區
中東和非洲
- 阿聯酋
- 沙特阿拉伯
- 南非

簡介目錄圖表

Product Code: TIPRE00029847

The biopharmaceuticals market is expected to grow from US$ 3,29,966.22 million in 2022 to US$ 7,00,873.94 million by 2028; it is expected to grow at a CAGR of 13.4% from 2022 to 2028.

Rising applications in cancer therapeutics and potential to treat rare diseases are a few factors driving the biopharmaceuticals market growth.

North America is likely to continue its dominance in the biopharmaceuticals market during the forecast period. The US held the largest market share in this region in 2022. According to The International Trade Administration report, the US is the largest market for biopharmaceuticals accounting for approximately a third of the global biopharmaceutical market with pioneers in biopharmaceutical R&D. Also, the economic impact of the biopharmaceutical industry in the US economy is substantial. In 2018, over US$ 17 billion in biopharmaceutical exports were from most foreign-owned firms operating in the US. Moreover, in the same year, these majority foreign-owned firms spent ~US$ 20 billion on R&D.

On the other hand, Asia Pacific is expected to witness lucrative growth over the forecast period. This is due to China's biopharmaceutical industry undergoing a tremendous shift evolving from a generics-focused to a thriving innovation hub. Additionally, promoting industrialization and growing application of novel drugs and high-end medical devices and techniques are a few factors responsible for the growth of the biopharmaceuticals market in China. For instance, in March 2022, CANbridge Pharmaceuticals Inc., a pioneer China-based biopharmaceutical company, announced that the Taiwan Food and Drug Administration (TFDA) had accepted the New Drug Application/Orphan Drug Registration (NDA/ODR) for "CAN108 [maralixibat oral solution (LIVMARLI TM)]" intended for treating cholestatic pruritus among patients suffering from Alagille syndrome (ALGS) for 1 year of age and older. Such aforementioned factors are responsible for influential growth of biopharmaceuticals market in Asia Pacific during 2022-2028.

Market Opportunity

Accelerated Clinical Trials

Accelerated progress of clinical trials will ultimately result in the development and commercialization of new drugs targeting rare as well as common inherited diseases. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, acute leukemia that has been historically difficult to diagnose. Also, the disease is extremely rare-it impacts fewer than 1,000 patients in the US annually. In December 2018, Tagraxofusp became the first therapy approved for treating BPDCN, which then became the standard care method for treating these patients. During clinical trials, more than 90% of the patients who never received any treatment responded to therapy.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that weakens muscles, impacts physical function, and causes irreversible brain and spinal cord damage. To date, only 2 products are approved for slowing the functional decline associated with ALS. The accelerated clinical trials for developing new products targeting ALS are in progress. For example, antisense oligonucleotides (ASOs) have been showing promising results in clinical trials involving patients suffering from ALS. Further, different gene therapy approaches, targeting multiple mutations in patients for both sporadic ALS and familial ALS, are also in clinical trials.

Thus, an extensive pipeline of biopharmaceuticals that are in clinical trials is expected to offer lucrative growth opportunities to the biopharmaceuticals market in the coming years.

Based on product type, the biopharmaceuticals market is segmented into monooclonal antibodies, recombinant vaccines, conventional vaccine, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell and gene therapies, cytokines/interferon/interleukins, and others (mRNA-based therapeutics, etc.). The monoclonal antibodies segment held the largest market share in 2022 and is anticipated to register a significant CAGR during the forecast period. Monoclonal antibodies (mABs) are at the forefront of the biological products market and will continue to lead resource investment in the biopharmaceutical market by providing innovative therapeutic solutions intended for immune oncology and immunotherapy. mABs treat multiple diseases such as cancer, organ transplant rejection, inflammatory and autoimmune diseases, allergies, infections, COVID-19, osteoporosis, eye disorders, migraines, high cholesterol, and nervous system disorders. There are many different mABs used to treat cancer. They work in different ways to kill or stop cancer cells from growing. They all have names that include "mab" at the end of their generic name-for example, trastuzumab (Herceptin) and rituximab (Mabthera). Approvals of monoclonal antibody therapies by the US Food and Drug Administration (FDA) have increased since the first drug containing monoclonal antibodies was approved for humans. A major benefit of monoclonal antibodies is that they have successfully been used to manufacture drugs to treat certain diseases, such as some cancers. Another benefit of monoclonal antibodies is that they are more accurate than other treatments. This improves effectiveness and can reduce some side effects. The quality of the monoclonal antibodies is standard for all production batches, which is important for both therapeutic use and diagnostics. Such aforementioned factors are responsible for the segment growth, thereby fueling the biopharmaceuticals market during the forecast period.

Based on application, the biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. The oncology segment held the largest share of the market in 2022; however, the inflammatory and infectious diseases segment is expected to register the highest CAGR during the forecast period. According to the National Institute of Health (NIH) report, cancer is a complex invasive genetic disease-causing significant mortality globally. For example, protein-based biopharmaceuticals have significantly extended the lives of millions of cancer patients. Further, various top companies entered a research collaboration for developing novel therapeutics-based targeted protein-based technology for cancer treatment. For instance, in April 2022, Ubix Therapeutics announced a collaboration with SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer technology for cancer treatment. Such aforementioned factors are responsible for the segment growth, thereby contributing to the market growth of biopharmaceuticals during the forecast period.

Food and Drug Administration, Japan External Trade Organization, Saudi Food and Drug Authority (SFDA), and American Hospital Association (AHA) are the primary and secondary sources referred to while preparing the report on the biopharmaceuticals market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the biopharmaceuticals market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global biopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Biopharmaceuticals Market - by Product Type
- 1.3.2 Global Biopharmaceuticals Market - by Application
- 1.3.3 Global Biopharmaceuticals Market - by Geography

2. Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Biopharmaceuticals Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 Middle East & Africa PEST Analysis
- 4.2.5 South & Central America PEST Analysis
4.3 Expert's Opinion

5. Biopharmaceuticals Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Application in Cancer Therapeutics
- 5.1.2 Potential to Treat Rare Diseases
5.2 Market Restraints
- 5.2.1 High Cost of Manufacturing Infrastructure
5.3 Market Opportunities
- 5.3.1 Accelerated Clinical Trials
5.4 Future Trends
- 5.4.1 Contract Manufacturing of Biopharmaceuticals
5.5 Impact Analysis

6. Biopharmaceuticals Market - Global Analysis

6.1 Global Biopharmaceuticals Market Revenue Forecast and Analysis
6.2 Global Biopharmaceuticals Market, by Geography - Forecast and Analysis
6.3 Market Positioning of Key Players

7. Global Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
7.3 Monoclonal Antibodies
- 7.3.1 Overview
- 7.3.2 Monoclonal Antibodies: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Recombinant Vaccines
- 7.4.1 Overview
- 7.4.2 Recombinant Vaccines: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.1 Cancer Vaccine
    - 7.4.2.1.1 Overview
    - 7.4.2.1.2 Cancer Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.2 Malaria Vaccine
    - 7.4.2.2.1 Overview
    - 7.4.2.2.2 Malaria Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.3 Ebola Vaccine
    - 7.4.2.3.1 Overview
    - 7.4.2.3.2 Ebola Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.4 Hepatitis-B Vaccine
    - 7.4.2.4.1 Overview
    - 7.4.2.4.2 Hepatitis-B Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.5 Tetanus Vaccine
    - 7.4.2.5.1 Overview
    - 7.4.2.5.2 Tetanus Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.6 Diphtheria Vaccine
    - 7.4.2.6.1 Overview
    - 7.4.2.6.2 Diphtheria Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.7 Cholera Vaccine
    - 7.4.2.7.1 Overview
    - 7.4.2.7.2 Cholera Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.4.2.8 Others
    - 7.4.2.8.1 Overview
    - 7.4.2.8.2 Others: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Conventional Vaccines
- 7.5.1 Overview
- 7.5.2 Conventional Vaccines: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.1 Polio Vaccine
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Polio Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.2 Pox Vaccine
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Pox Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.5.2.3 Other Conventional Vaccine
    - 7.5.2.3.1 Overview
    - 7.5.2.3.2 Other Conventional Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Recombinant Growth Factors
- 7.6.1 Overview
- 7.6.2 Recombinant Growth Factors: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.1 Erythropoietin
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Erythropoietin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.6.2.2 Granulocyte Colony Stimulating Factor
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Purified Proteins
- 7.7.1 Overview
- 7.7.2 Purified Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.1 Leukemia Inhibitory Factor (LIF)
    - 7.7.2.1.1 Overview
    - 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.2 P53 Protein
    - 7.7.2.2.1 Overview
    - 7.7.2.2.2 P53 Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.3 P38 Protein
    - 7.7.2.3.1 Overview
    - 7.7.2.3.2 P38 Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.7.2.4 Other Purified Proteins
    - 7.7.2.4.1 Overview
    - 7.7.2.4.2 Other Purified Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Recombinant Proteins
- 7.8.1 Overview
- 7.8.2 Recombinant Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.1 Serum Albumin
    - 7.8.2.1.1 Overview
    - 7.8.2.1.2 Serum Albumin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.2 Amyloid Protein
    - 7.8.2.2.1 Overview
    - 7.8.2.2.2 Amyloid Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.3 Defensin
    - 7.8.2.3.1 Overview
    - 7.8.2.3.2 Defensin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.8.2.4 Transferrin
    - 7.8.2.4.1 Overview
    - 7.8.2.4.2 Transferrin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Recombinant Hormones
- 7.9.1 Overview
- 7.9.2 Recombinant Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.1 Recombinant Human Growth Hormones
    - 7.9.2.1.1 Overview
    - 7.9.2.1.2 Recombinant Human Growth Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.2 Recombinant Insulin
    - 7.9.2.2.1 Overview
    - 7.9.2.2.2 Recombinant Insulin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.9.2.3 Other Recombinant Hormones
    - 7.9.2.3.1 Overview
    - 7.9.2.3.2 Other Recombinant Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Recombinant Enzymes
- 7.10.1 Overview
- 7.10.2 Recombinant Enzymes: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.1 Enterokinase
    - 7.10.2.1.1 Overview
    - 7.10.2.1.2 Enterokinase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.2 Cyclase
    - 7.10.2.2.1 Overview
    - 7.10.2.2.2 Cyclase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.3 Caspase
    - 7.10.2.3.1 Overview
    - 7.10.2.3.2 Caspase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.10.2.4 Cathepsin
    - 7.10.2.4.1 Overview
    - 7.10.2.4.2 Cathepsin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.11 Cell and Gene Therapies
- 7.11.1 Overview
- 7.11.2 Cell and Gene Therapies: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.1 Allogenic Products
    - 7.11.2.1.1 Overview
    - 7.11.2.1.2 Allogenic Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.2 Autologous Products
    - 7.11.2.2.1 Overview
    - 7.11.2.2.2 Autologous Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  - 7.11.2.3 Acellular Products
    - 7.11.2.3.1 Overview
    - 7.11.2.3.2 Acellular Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.12 Cytokines/Interferon/Interleukins
- 7.12.1 Overview
- 7.12.2 Cytokines/Interferon/Interleukins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
7.13 Others (mRNA Based Therapeutics, etc.)
- 7.13.1 Overview
- 7.13.2 Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

8.1 Overview
8.2 Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
8.3 Oncology
- 8.3.1 Overview
- 8.3.2 Oncology: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Inflammatory and Infectious Diseases
- 8.4.1 Overview
- 8.4.2 Inflammatory and Infectious Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.5 Autoimmune Disorders
- 8.5.1 Overview
- 8.5.2 Autoimmune Disorders: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolic Disorders: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.7 Hormonal Disorders and Growth Failure
- 8.7.1 Overview
- 8.7.2 Hormonal Disorders and Growth Failure: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.8 Cardiovascular Diseases
- 8.8.1 Overview
- 8.8.2 Cardiovascular Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.9 Neurological Diseases
- 8.9.1 Overview
- 8.9.2 Neurological Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
8.10 Other Therapeutic Applications
- 8.10.1 Overview
- 8.10.2 Other Therapeutic Applications: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. Biopharmaceuticals Market - Revenue and Forecast to 2028 - Geographic Analysis

9.1 North America: Biopharmaceuticals Market
- 9.1.1 Overview
- 9.1.2 North America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
- 9.1.3 North America: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
  - 9.1.3.1 North America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
  - 9.1.3.2 North America: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
  - 9.1.3.3 North America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
  - 9.1.3.4 North America: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
  - 9.1.3.5 North America: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
  - 9.1.3.6 North America: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
  - 9.1.3.7 North America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
  - 9.1.3.8 North America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
- 9.1.4 North America: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.1.4.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.4.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.4.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.4.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.4.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.4.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.4.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.4.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.4.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.1.4.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.4.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.4.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.4.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.4.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.4.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.4.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.4.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.4.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.1.4.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.1.4.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.1.4.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.1.4.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.1.4.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.1.4.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.1.4.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.1.4.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.1.4.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.1.4.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.2 Europe: Biopharmaceuticals Market
- 9.2.1 Overview
- 9.2.2 Europe: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.3 Europe: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
  - 9.2.3.1 Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
  - 9.2.3.2 Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
  - 9.2.3.3 Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
  - 9.2.3.4 Europe: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
  - 9.2.3.5 Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
  - 9.2.3.6 Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
  - 9.2.3.7 Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
  - 9.2.3.8 Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
- 9.2.4 Europe: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
- 9.2.5 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  - 9.2.5.1 United Kingdom: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.2.5.2 Germany: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.2.2 Germany: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.2.5.3 France: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.3.1 France: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.3.2 France: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.2.5.4 Italy: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.4.2 Italy: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.2.5.5 Spain: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.5.2 Spain: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.2.5.6 Rest of Europe: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.2.5.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.2.5.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.2.5.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.2.5.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.2.5.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.2.5.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.2.5.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.2.5.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.2.5.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.3 Asia Pacific: Biopharmaceuticals Market
- 9.3.1 Overview
- 9.3.2 Asia Pacific: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
- 9.3.3 Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
  - 9.3.3.1 Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
  - 9.3.3.2 Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
  - 9.3.3.3 Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
  - 9.3.3.4 Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
  - 9.3.3.5 Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
  - 9.3.3.6 Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
  - 9.3.3.7 Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
  - 9.3.3.8 Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
- 9.3.4 Asia Pacific: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
- 9.3.5 Asia Pacific: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  - 9.3.5.1 China: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.1.1 China: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.1.1.1 China: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.1.1.2 China: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.1.1.3 China: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.1.1.4 China: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.1.1.5 China: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.1.1.6 China: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.1.1.7 China: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.1.1.8 China: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.1.2 China: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.3.5.2 Japan: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.2.1 Japan: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.2.1.1 Japan: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.2.1.2 Japan: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.2.1.3 Japan: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.2.1.4 Japan: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.2.1.5 Japan: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.2.1.6 Japan: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.2.1.7 Japan: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.2.1.8 Japan: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.2.2 Japan: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.3.5.3 India: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.3.1 India: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.3.1.1 India: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.3.1.2 India: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.3.1.3 India: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.3.1.4 India: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.3.1.5 India: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.3.1.6 India: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.3.1.7 India: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.3.1.8 India: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.3.2 India: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.3.5.4 South Korea: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.4.1 South Korea: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.4.1.1 South Korea: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.4.1.2 South Korea: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.4.1.3 South Korea: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.4.1.4 South Korea: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.4.1.5 South Korea: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.4.1.6 South Korea: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.4.1.7 South Korea: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.4.1.8 South Korea: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.4.2 South Korea: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.3.5.5 Australia: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.5.1 Australia: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.5.1.1 Australia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.5.1.2 Australia: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.5.1.3 Australia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.5.1.4 Australia: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.5.1.5 Australia: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.5.1.6 Australia: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.5.1.7 Australia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.5.1.8 Australia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.5.2 Australia: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.3.5.6 Rest of Asia Pacific: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.3.5.6.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.3.5.6.1.1 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.6.1.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.3.5.6.1.3 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.3.5.6.1.4 Rest of Asia Pacific: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.3.5.6.1.5 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.3.5.6.1.6 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.3.5.6.1.7 Rest of Asia Pacific: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.3.5.6.1.8 Rest of Asia Pacific: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.3.5.6.2 Rest of Asia Pacific: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
9.4 Middle East & Africa Biopharmaceuticals Market
- 9.4.1 Overview
- 9.4.2 Middle East & Africa: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4.3 Middle East & Africa: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
  - 9.4.3.1 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
  - 9.4.3.2 Middle East & Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
  - 9.4.3.3 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
  - 9.4.3.4 Middle East & Africa: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
  - 9.4.3.5 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
  - 9.4.3.6 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
  - 9.4.3.7 Middle East & Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
  - 9.4.3.8 Middle East & Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
- 9.4.4 Middle East & Africa: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
- 9.4.5 Middle East & Africa: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  - 9.4.5.1 UAE: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.4.5.1.1 UAE: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.4.5.1.1.1 UAE: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.1.1.2 UAE: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.1.1.3 UAE: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.4.5.1.1.4 UAE: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.4.5.1.1.5 UAE: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.4.5.1.1.6 UAE: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.4.5.1.1.7 UAE: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.4.5.1.1.8 UAE: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.4.5.1.2 UAE: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.4.5.2 Saudi Arabia: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.4.5.2.1 Saudi Arabia: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.4.5.2.1.1 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.2.1.2 Saudi Arabia: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.2.1.3 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.4.5.2.1.4 Saudi Arabia: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.4.5.2.1.5 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.4.5.2.1.6 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.4.5.2.1.7 Saudi Arabia: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.4.5.2.1.8 Saudi Arabia: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.4.5.2.2 Saudi Arabia: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
  - 9.4.5.3 South Africa: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    - 9.4.5.3.1 South Africa: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
    - 9.4.5.3.1.1 South Africa: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.3.1.2 South Africa: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
    - 9.4.5.3.1.3 South Africa: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
    - 9.4.5.3.1.4 South Africa: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
    - 9.4.5.3.1.5 South Africa: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
    - 9.4.5.3.1.6 South Africa: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
    - 9.4.5.3.1.7 South Africa: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
    - 9.4.5.3.1.8 South Africa: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
    - 9.4.5.3.2 South Africa: Biopharmaceuticals Mark

簡介目錄圖表

List Of Tables

Table 1. North America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 2. North America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 6. North America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 7. North America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 8. North America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 9. North America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 10. North America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 11. United States Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 12. United States Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 13. United States Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 14. United States Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 15. United States Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 16. United States Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 17. United States Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 18. United States Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 19. United States Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 20. United States Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 21. Canada Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 22. Canada Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 23. Canada Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 24. Canada Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 25. Canada Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 26. Canada Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 27. Canada Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 28. Canada Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 29. Canada Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 30. Canada Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 31. Mexico Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. Mexico Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 33. Mexico Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 34. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 35. Mexico Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 36. Mexico Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 37. Mexico Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 38. Mexico Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 39. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 40. Mexico Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 41. Europe Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 42. Europe Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 43. Europe Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 44. Europe Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 45. Europe Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 46. Europe Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 47. Europe Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 48. Europe Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 49. Europe Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 50. Europe Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 51. United Kingdom Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 52. United Kingdom Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 53. United Kingdom Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 54. United Kingdom Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 55. United Kingdom Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 56. United Kingdom Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 57. United Kingdom Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 58. United Kingdom Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 59. United Kingdom Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 60. United Kingdom Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 61. Germany Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 62. Germany Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 63. Germany Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 64. Germany Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 65. Germany Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 66. Germany Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 67. Germany Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 68. Germany Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 69. Germany Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 70. Germany Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 71. France Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 72. France Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 73. France Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 74. France Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 75. France Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 76. France Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 77. France Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 78. France Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 79. France Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 80. France Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 81. Italy Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 82. Italy Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 83. Italy Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 84. Italy Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 85. Italy Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 86. Italy Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 87. Italy Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 88. Italy Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 89. Italy Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 90. Italy Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 91. Spain Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. Spain Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 93. Spain Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 94. Spain Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 95. Spain Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 96. Spain Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 97. Spain Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 98. Spain Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 99. Spain Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 100. Spain Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 101. Rest of Europe Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 102. Rest of Europe Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Europe Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Europe Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Europe Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Europe Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Europe Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Europe Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 109. Rest of Europe Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 110. Rest of Europe Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 111. Asia Pacific Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 112. Asia Pacific Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 113. Asia Pacific Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 114. Asia Pacific Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 115. Asia Pacific Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 116. Asia Pacific Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 117. Asia Pacific Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 118. Asia Pacific Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 119. Asia Pacific Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 120. Asia Pacific Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 121. China Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 122. China Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 123. China Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 124. China Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 125. China Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 126. China Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 127. China Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 128. China Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 129. China Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 130. China Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 131. Japan Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 132. Japan Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 133. Japan Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 134. Japan Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 135. Japan Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 136. Japan Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 137. Japan Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 138. Japan Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 139. Japan Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 140. Japan Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 141. India Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 142. India Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 143. India Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 144. India Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 145. India Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 146. India Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 147. India Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 148. India Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 149. India Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 150. India Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 151. South Korea Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 152. South Korea Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 153. South Korea Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 154. South Korea Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 155. South Korea Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 156. South Korea Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 157. South Korea Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 158. South Korea Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 159. South Korea Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 160. South Korea Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 161. Australia Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 162. Australia Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 163. Australia Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 164. Australia Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 165. Australia Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 166. Australia Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 167. Australia Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 168. Australia Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 169. Australia Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 170. Australia Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 171. Rest of Asia Pacific Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 172. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 173. Rest of Asia Pacific Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 174. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 175. Rest of Asia Pacific Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 176. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 177. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 178. Rest of Asia Pacific Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 179. Rest of Asia Pacific Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 180. Rest of Asia Pacific Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 181. Middle East & Africa Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 182. Middle East & Africa Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 183. Middle East & Africa Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 184. Middle East & Africa Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 185. Middle East & Africa Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 186. Middle East & Africa Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 187. Middle East & Africa Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 188. Middle East & Africa Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 189. Middle East & Africa Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 190. Middle East & Africa Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 191. UAE Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 192. UAE Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 193. UAE Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 194. UAE Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 195. UAE Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 196. UAE Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 197. UAE Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 198. UAE Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 199. UAE Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 200. UAE Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 201. Saudi Arabia Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 202. Saudi Arabia Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 203. Saudi Arabia Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 204. Saudi Arabia Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 205. Saudi Arabia Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 206. Saudi Arabia Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 207. Saudi Arabia Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 208. Saudi Arabia Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 209. Saudi Arabia Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 210. Saudi Arabia Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 211. South Africa Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 212. South Africa Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 213. South Africa Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 214. South Africa Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 215. South Africa Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 216. South Africa Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 217. South Africa Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 218. South Africa Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 219. South Africa Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 220. South Africa Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 221. Rest of Middle East & Africa Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 222. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 223. Rest of Middle East & Africa Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 224. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 225. Rest of Middle East & Africa Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 226. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 227. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 228. Rest of Middle East & Africa Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 229. Rest of Middle East & Africa Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 230. Rest of Middle East & Africa Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 231. South & Central America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 232. South & Central America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 233. South & Central America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 234. South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 235. South & Central America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 236. South & Central America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 237. South & Central America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 238. South & Central America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 239. South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 240. South & Central America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 241. Brazil Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 242. Brazil Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 243. Brazil Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 244. Brazil Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 245. Brazil Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 246. Brazil Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 247. Brazil Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 248. Brazil Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 249. Brazil Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 250. Brazil Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 251. Argentina Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 252. Argentina Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 253. Argentina Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 254. Argentina Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 255. Argentina Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 256. Argentina Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 257. Argentina Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 258. Argentina Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 259. Argentina Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 260. Argentina Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 261. Rest of South & Central America Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
Table 262. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 263. Rest of South & Central America Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
Table 264. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
Table 265. Rest of South & Central America Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 266. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
Table 267. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
Table 268. Rest of South & Central America Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
Table 269. Rest of South & Central America Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
Table 270. Rest of South & Central America Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
Table 271. Recent Organic Growth Strategies in Biopharmaceuticals Market
Table 272. Recent Inorganic Growth Strategies in the Biopharmaceuticals Market
Table 273. Glossary of Terms

List Of Figures

Figure 1. Biopharmaceuticals Market Segmentation
Figure 2. Biopharmaceuticals Market, by Region
Figure 3. Global Biopharmaceuticals Market Overview
Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in Biopharmaceuticals Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Biopharmaceuticals Market, by Geography (US$ Million)
Figure 7. Global Biopharmaceuticals Market - Leading Country Markets (US$ Million)
Figure 8. Global Biopharmaceuticals Market - Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East & Africa: PEST Analysis
Figure 13. South & Central America: PEST Analysis
Figure 14. Experts' Opinion
Figure 15. Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
Figure 16. Global Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
Figure 17. Global Biopharmaceuticals Market, by Geography - Forecast and Analysis (2021-2028)
Figure 18. Market Positioning of Key Players in Biopharmaceuticals Market
Figure 19. Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
Figure 20. Monoclonal Antibodies: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Recombinant Vaccines: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. Cancer Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Malaria Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Ebola Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. Hepatitis-B Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Tetanus Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Diphtheria Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. Cholera Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Others: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Conventional Vaccines: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Polio Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. Pox Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Other Conventional Vaccine: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Recombinant Growth Factors: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. Erythropoietin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. Granulocyte Colony Stimulating Factor: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. Purified Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. Leukemia Inhibitory Factor (LIF): Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. P53 Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. P38 Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Other Purified Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 42. Recombinant Proteins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Serum Albumin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 44. Amyloid Protein: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Defensin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. Transferrin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Recombinant Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Recombinant Human Growth Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Recombinant Insulin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. Other Recombinant Hormones: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 51. Recombinant Enzymes: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. Enterokinase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 53. Cyclase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. Caspase: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. Cathepsin: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Cell and Gene Therapies: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 57. Allogenic Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. Autologous Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. Acellular Products: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. Cytokines/Interferon/Interleukins: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Others (mRNA Based Therapeutics, etc.): Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Global Biopharmaceuticals Market, by Application 2021 & 2028 (%)
Figure 63. Oncology: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Inflammatory and Infectious Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 65. Autoimmune Disorders: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 66. Metabolic Disorders: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. Hormonal Disorders and Growth Failure: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. Cardiovascular Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. Neurological Diseases: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. Other Therapeutic Applications: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 71. North America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 72. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 73. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 74. United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 75. Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 76. Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 77. Europe: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 78. Europe Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 79. Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 80. United Kingdom: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 81. Germany: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 82. France: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 83. Italy: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 84. Spain: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 85. Rest of Europe: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 86. Asia Pacific: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 87. Asia Pacific Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 88. China: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 89. Japan: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 90. India: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 91. South Korea: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 92. Australia: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 93. Rest of Asia Pacific: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 94. Middle East & Africa: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 95. Middle East & Africa Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 96. UAE: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 97. Saudi Arabia: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 98. South Africa: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 99. Rest of Middle East & Africa: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 100. South & Central America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
Figure 101. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 102. South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 103. Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 104. Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 105. Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
Figure 106. IMPACT OF COVID-19 PANDEMIC IN NORTH AMERICAN COUNTRY MARKETS
Figure 107. IMPACT OF COVID-19 PANDEMIC IN EUROPEAN COUNTRY MARKETS
Figure 108. IMPACT OF COVID-19 PANDEMIC IN ASIA PACIFIC COUNTRY MARKETS
Figure 109. IMPACT OF COVID-19 PANDEMIC IN MIDDLE EAST & AFRICA COUNTRY MARKETS
Figure 110. IMPACT OF COVID-19 PANDEMIC ON SOUTH & CENTRAL AMERICAN COUNTRY MARKETS
Figure 111. Growth Strategies in Biopharmaceuticals Market